Healthcare Industry News: ZELTIQ
News Release - May 8, 2012
ZELTIQ(R) Aesthetics Promotes Joshua T. Brumm to Senior Vice PresidentPLEASANTON, Calif., May 8, 2012 -- (Healthcare Sales & Marketing Network) -- ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the Board of Directors has promoted Chief Financial Officer Joshua Brumm to Senior Vice President, from Vice President. Mr. Brumm has served as Vice President and Chief Financial Officer since January 2012. Prior to that, he served as Vice President, Corporate Development and Investor Relations. Mr. Brumm will continue to oversee all financial operations, corporate development, information technology and investor relations functions.
About ZELTIQ Aesthetics
ZELTIQ(R) Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
Source: ZELTIQ Aesthetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.